Double-Blind Trial of Aminophylline in Status Asthmaticus

PEDIATRICS ◽  
1971 ◽  
Vol 48 (4) ◽  
pp. 642-646
Author(s):  
William E. Pierson ◽  
C. Warren Bierman ◽  
Stanley J. Stamm ◽  
Paul P. VanArsdel
Keyword(s):  
Adverse Effects ◽  
Therapeutic Effect ◽  
Status Asthmaticus ◽  
Controlled Trial ◽  
Hospitalized Children ◽  
Double Blind Trial ◽  
Ventilatory Function ◽  
Double Blind ◽  
Medical Supervision ◽  
Blind Trial

Significant improvement in ventilatory function without observable adverse effects has been demonstrated by this double-blind controlled trial of intravenous aminophylline in status asthmaticus. Aminophylline appears to have a beneficial therapeutic effect when given in addition to other accepted medications in appropriate dosage and under careful medical supervision to hospitalized children with status asthmaticus.

Aminophylline in Status Asthmaticus: Some Questions

PEDIATRICS ◽  
1972 ◽  
Vol 49 (4) ◽  
pp. 631-632
Author(s):  
Kelsy J. Caplinger
Keyword(s):  
Side Effects ◽  
Status Asthmaticus ◽  
Double Blind Trial ◽  
Ventilatory Function ◽  
Double Blind ◽  
Blind Trial ◽  
Good Improvement

The report of a double blind trial of aminophylline in status asthmaticus by Pierson, et al. seems indeed to have shown that significant improvement in ventilatory function resulted without serious side effects. Aminophylline toxicity is a very real and potentially serious complication of the treatment of status asthmaticus. There is a wide variation in the recommended children's dose of aminophylline. Since this study showed apparent good improvement in ventilatory function (when used with other accepted medications in appropriate doses) and serious side effects were avoided, it would be of interest to know the dose of aminophylline required in these patients.

A Double-Blind Trial of Long-Term Lithium Therapy in Mental Defectives

1974 ◽  
Vol 124 (578) ◽  
pp. 52-57 ◽  
Author(s):  
Graham J. Naylor ◽  
J. M. Donald ◽  
David Le Poidevin ◽  
Andrew H. Reid
Keyword(s):  
Therapeutic Effect ◽  
Affective Disorders ◽  
Lithium Therapy ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Mental Defectives

The therapeutic effect of lithium in mania was first described by Cade (1949), but the possibility that lithium could have a prophylactic action in recurrent affective disorders was not suggested until some years later (Hartigan, 1963; Baastrup, 1964). The early studies of the prophylactic action of lithium were open trials, in which both investigator and patient knew that the patient was receiving the drug. More recently, controlled double-blind studies have confirmed these early reports (Melia, 1970; Coppenet al., 1971; Cundallet al., 19712).

A Double-Blind Trial of Corticosteroid Therapy in Status Asthmaticus

PEDIATRICS ◽  
1974 ◽  
Vol 54 (3) ◽  
pp. 282-288
Author(s):  
William E. Pierson ◽  
C. Warren Bierman ◽  
V. C. Kelley
Keyword(s):  
Beneficial Effect ◽  
Corticosteroid Therapy ◽  
Adverse Reactions ◽  
Status Asthmaticus ◽  
Control Group ◽  
Double Blind Trial ◽  
Ventilatory Function ◽  
Double Blind ◽  
Pharmacologically Active ◽  
Betamethasone And Dexamethasone

Initial treatment of status asthmaticus with corticosteroids caused significant improvement in arterial hypoxemia that did not occur in the control group. This improvement was not dependent upon changes in ventilatory function (FVC, FEV1). Betamethasone, hydrocortisone, and dexamethasone all appeared to have this beneficial effect. Both betamethasone and dexamethasone appeared to have the added advantage of higher unbound (pharmacologically active) corticosteroid levels. No toxic or adverse reactions were noted in this 24-hour study. Thus, corticosteroid therapy is indicated early in treatment of status asthmaticus, as withholding it needlessly exposes the patient to the risks of prolonged hypoxemia.

scholarly journals Can Homeopaths Detect Homeopathic Medicines by Dowsing? A Randomized, Double-Blind, Placebo-Controlled Trial

2002 ◽  
Vol 95 (4) ◽  
pp. 189-191 ◽  
Author(s):  
R McCarney ◽  
P Fisher ◽  
F Spink ◽  
G Flint ◽  
R van Haselen
Keyword(s):  
Problem Solving ◽  
Confidence Interval ◽  
Controlled Trial ◽  
Double Blind Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Blind Trial ◽  
Objective Information ◽  
Homeopathic Medicine

Dowsing is a method of problem-solving that uses a motor automatism, amplified through a pendulum or similar device. In a homeopathic context, it is used as an aid to prescribing and as a tool to identify miasm or toxin load. A randomized double-blind trial was conducted to determine whether six dowsing homeopaths were able to distinguish between Bryonia in a 12c potency and placebo by use of dowsing alone. The homeopathic medicine Bryonia was correctly identified in 48.1% of bottle pairs (n=156; 95% confidence interval 40.2%, 56.0%; P=0.689). These results, wholly negative, add to doubts whether dowsing in this context can yield objective information.

Differences in Serum Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib in a Randomized, Double-blind Trial in Osteoarthritis Patients

2020 ◽  
Vol 19 (2) ◽  
pp. 190-201 ◽  
Author(s):  
Sandi L. Navarro ◽  
Marta Herrero ◽  
Helena Martinez ◽  
Yuzheng Zhang ◽  
Jon Ladd ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Multiple Testing ◽  
Serum Proteins ◽  
Double Blind Trial ◽  
Protein Biomarkers ◽  
Double Blind ◽  
Baseline Serum ◽  
Blind Trial ◽  
Anti Inflammatory

Background: Non-steroidal anti-inflammatory drugs, e.g., celecoxib, are commonly used for inflammatory conditions, but can be associated with adverse effects. Combined glucosamine hydrochloride plus chondroitin sulfate (GH+CS) are commonly used for joint pain and have no known adverse effects. Evidence from in vitro, animal and human studies suggest that GH+CS have anti-inflammatory activity, among other mechanisms of action. Objective: We evaluated the effects of GH+CS versus celecoxib on a panel of 20 serum proteins involved in inflammation and other metabolic pathways. Methods: Samples were from a randomized, parallel, double-blind trial of pharmaceutical grade 1500 mg GH + 1200 mg CS (n=96) versus 200 mg celecoxib daily (n=93) for 6- months in knee osteoarthritis (OA) patients. Linear mixed models adjusted for age, sex, body mass index, baseline serum protein values, and rescue medicine use assessed the intervention effects of each treatment arm adjusting for multiple testing. Results: All serum proteins except WNT16 were lower after treatment with GH+CS, while about half increased after celecoxib. Serum IL-6 was significantly reduced (by 9%, P=0.001) after GH+CS, and satisfied the FDR <0.05 threshold. CCL20, CSF3, and WNT16 increased after celecoxib (by 7%, 9% and 9%, respectively, P<0.05), but these serum proteins were no longer statistically significant after controlling for multiple testing. Conclusion: The results of this study using samples from a previously conducted trial in OA patients, demonstrate that GH+CS reduces circulating IL-6, an inflammatory cytokine, but is otherwise comparable to celecoxib with regard to effects on other circulating protein biomarkers.

A Controlled Trial of Prothipendyl (Tolnate) in Mentally Subnormal Patients

1966 ◽  
Vol 112 (482) ◽  
pp. 95-100 ◽  
Author(s):  
Margaret E. McKenzie ◽  
Daphne Roswell-Harris
Keyword(s):  
Side Effects ◽  
Controlled Trial ◽  
Double Blind Trial ◽  
Double Blind ◽  
Blind Trial ◽  
Preliminary Group

The improvement shown by a group of severely subnormal patients after treatment with prothipendyl (Tolnate) was the reason for conducting a double-blind trial to assess the effects of the drug, while attempts were made to control the environment. The preliminary group studied consisted of 35 patients of both sexes, of all ages, who all exhibited pronounced behaviour disorders and presented acute problems in nursing and management. None had responded adequately to the more widely used tranquillizers and sedatives, but all except two patients with superadded depression, responded to prothipendyl in some measure without side effects.

Amitriptyline and Perphenazine in Depressive Illness a Controlled Trial

1967 ◽  
Vol 113 (495) ◽  
pp. 195-199 ◽  
Author(s):  
Ijaz Haider
Keyword(s):  
Controlled Trial ◽  
Depressive Illness ◽  
Double Blind Trial ◽  
Double Blind ◽  
Matching Placebo ◽  
Blind Trial ◽  
Amitriptyline Hydrochloride

This paper describes a “double-blind” trial comparing ‘Triptafen’ tablets—each containing amitriptyline hydrochloride 25 mg. and perphenazine 2 mg.—with a matching placebo in the treatment of depressive illness.

scholarly journals Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. a double-blind trial

1997 ◽  
Vol 55 (3B) ◽  
pp. 536-541 ◽  
Author(s):  
Carlos Alberto Bordini ◽  
Marco Antônio Arruda ◽  
Marcelo Cedrinho Ciciarelli ◽  
José Geraldo Speciali
Keyword(s):  
Therapeutic Effect ◽  
Migraine Without Aura ◽  
Drug Withdrawal ◽  
Baseline Period ◽  
Global Evaluation ◽  
Double Blind Trial ◽  
Double Blind ◽  
Mean Frequency ◽  
Blind Trial

Fourty-five migraine without aura patients underwent a parallel double-blind trial aiming the comparison of the effects of propranolol 60 mg/day to flunarizine 10 mg/day and to propranolol 60 mg/day plus flunarizine 10 mg/day simultaneously. There were 3 groups, each one with 15 patients. After a 20-day-baseline period, each group received one kind of treatment during 120 days. Migraine index on propranolol was 23.4*. on flunarizine 18.7* and on both drugs 14.4*, mean frequency of attacks on propranolol was 1.26**, on flunarizine 1.2** and on both drugs 1.13** (*p<0.05, ** p < 0.01 compared to baseline) and global evaluation was reduced with all forms of treatment. It was not found statistical differences between groups, nevertheless there was a trend in the group using two drugs reaching lower values in migraine index, frequency of attacks and global evaluation. In individuals using flunarizine (alone or associated with propranolol) the therapeutic effect was largely maintained up to 45 days after drug withdrawal.

Double-Blind Trial of the New Analgesic and Anti-Inflammatory Drug Indoprofen in Post-Episiotomic Pain

1975 ◽  
Vol 3 (1) ◽  
pp. 16-20 ◽  
Author(s):  
S Pedronetto ◽  
F Gorini ◽  
V Mandelli ◽  
L M Fuccella
Keyword(s):  
Side Effects ◽  
Controlled Trial ◽  
Double Blind Trial ◽  
Analgesic Drug ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Inflammatory Drug ◽  
Blind Trial ◽  
Anti Inflammatory

A double-blind, placebo-controlled trial of indoprofen, a new anti-inflammatory and analgesic drug, was carried out in women with pain due to episiotomy. A single 100 mg dose of the drug proved to be significantly more active than placebo in decreasing pain and was devoid of any side-effects.

Sign in / Sign up

Export Citation Format

Share Document